Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377:1919–29. https://doi.org/10.1056/NEJMoa1709937.

Article  CAS  PubMed  Google Scholar 

Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. J Clin Oncol. 2022;40:1301–11. https://doi.org/10.1200/JCO.21.01308.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu T, Wu L, Gandhi S, Jing W, Nguyen QN, Chen A. Treatment-related pulmonary adverse events induced by chemoradiation and Durvalumab affect survival in locally advanced non-small cell lung cancer. Radiother Oncol. 2022;176:149–56. https://doi.org/10.1016/j.radonc.2022.10.002.

Article  CAS  PubMed  Google Scholar 

Bryant AK, Sankar K, Zhao L, Strohbehn GW, Elliott D, Moghanaki D, et al. De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer. Eur J Cancer. 2022;171:55–63. https://doi.org/10.1016/j.ejca.2022.04.033.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shaverdian N, Offin M, Shepherd AF, Hellmann MD, Gomez DR, Chaft JE, et al. Association between the early discontinuation of durvalumab and poor survival in patients with stage III NSCLC. JTO Clin Res Rep. 2021;2: 100197. https://doi.org/10.1016/j.jtocrr.2021.100197.

Article  PubMed  PubMed Central  Google Scholar 

Pennock M, Halmos B, Bodner W, Cheng H, Gucalp R, Ohri N. Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer. Clin Transl Radiat Oncol. 2023;41: 100643. https://doi.org/10.1016/j.ctro.2023.100643.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, et al. Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study. J Thorac Oncol. 2023;18:181–93. https://doi.org/10.1016/j.jtho.2022.10.003.

Article  CAS  PubMed  Google Scholar 

Harris SJ, Brown J, Lopez J, Yap TA. Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biol Med. 2016;13:171–93. https://doi.org/10.20892/j.issn.2095-3941.2016.0015.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11:3801. https://doi.org/10.1038/s41467-020-17670-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Filleron T, Bachelier M, Mazieres J, Pérol M, Meyer N, Martin E, et al. Assessment of treatment effects and long-term benefits in immune checkpoint inhibitor trials using the flexible parametric cure model. JAMA Netw Open. 2021;4: e2139573. https://doi.org/10.1001/jamanetworkopen.2021.39573.

Article  PubMed  PubMed Central  Google Scholar 

Lin EP-Y, Hsu C-Y, Berry L, Bunn P, Shyr Y. Analysis of cancer survival associated with immune checkpoint inhibitors after statistical adjustment. JAMA Netw Open. 2022;5: e2227211. https://doi.org/10.1001/jamanetworkopen.2022.27211.

Article  PubMed  PubMed Central  Google Scholar 

Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol. 2017;35:3807–14. https://doi.org/10.1200/JCO.2017.73.2289.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Horiguchi M, Uno H, Wei L-J. Patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab as a result of adverse events lived significantly longer than patients who continued treatment. J Clin Oncol. 2018;36:720–1. https://doi.org/10.1200/JCO.2017.76.0983.

Article  CAS  PubMed  Google Scholar 

Waterhouse DM, Garon EB, Chandler J, McCleod M, Hussein M, Jotte R, et al. Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non–small-cell lung cancer: checkmate 153. J Clin Oncol. 2020;38:3863–73. https://doi.org/10.1200/JCO.20.00131.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kobayashi H, Wakuda K, Naito T, Mamesaya N, Ko R, Ono A, et al. Continuous vs. fixed 2-year duration immune checkpoint inhibitor treatment of patients with non-small cell lung cancer: a single institution database analysis. Clin Lung Cancer. 2023;24:498–506. https://doi.org/10.1016/j.cllc.2023.06.005. (e3).

Article  CAS  PubMed  Google Scholar 

Sun L, Bleiberg B, Hwang W-T, Marmarelis ME, Langer CJ, Singh A, et al. Association between duration of immunotherapy and overall survival in advanced non-small cell lung cancer. JAMA Oncol. 2023;9:1075–82. https://doi.org/10.1001/jamaoncol.2023.1891.

Article  PubMed  PubMed Central  Google Scholar 

Jiang M, Hu Y, Lin G, Chen C. Dosing regimens of immune checkpoint inhibitors: attempts at lower dose, less frequency, shorter course. Front Oncol. 2022;12: 906251. https://doi.org/10.3389/fonc.2022.906251.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hirsch I, Goldstein DA, Tannock IF, Butler MO, Gilbert DC. Optimizing the dose and schedule of immune checkpoint inhibitors in cancer to allow global access. Nat Med. 2022;28:2236–7. https://doi.org/10.1038/s41591-022-02029-1.

Article  CAS  PubMed  Google Scholar 

Shintani T, Kishi N, Matsuo Y, Ogura M, Mitsuyoshi T, Araki N, et al. Incidence and risk factors of symptomatic radiation pneumonitis in non–small-cell lung cancer patients treated with concurrent chemoradiotherapy and consolidation durvalumab. Clin Lung Cancer. 2021;22:401–10. https://doi.org/10.1016/j.cllc.2021.01.017.

Article  CAS  PubMed  Google Scholar 

Kishi N, Matsuo Y, Shintani T, Ogura M, Mitsuyoshi T, Araki N, et al. Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer. J Radiat Res. 2022;64:142–53. https://doi.org/10.1093/jrr/rrac057.

Article  CAS  PubMed Central  Google Scholar 

Cho IS, Chae YR, Kim JH, Yoo HR, Jang SY, Kim GR, et al. Statistical methods for elimination of guarantee- time bias in cohort studies: a simulation study. BMC Med Res Methodol. 2017;17:126. https://doi.org/10.1186/s12874-017-0405-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tatsuno S, Doi H, Okada W, Inoue E, Nakamatsu K, Tanooka M, et al. Risk factors for radiation pneumonitis after rotating gantry intensity-modulated radiation therapy for lung cancer. Sci Rep. 2022;12:590. https://doi.org/10.1038/s41598-021-04601-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baverel PG, Dubois VFS, Jin CY, Zheng Y, Song X, Jin X, et al. Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status. Clin Pharmacol Ther. 2018;103:631–42. https://doi.org/10.1002/cpt.982.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Denault M-H, Kuang S, Shokoohi A, Leung B, Liu M, Berthelet E, et al. Comparison of 2-weekly versus 4-weekly durvalumab consolidation for locally advanced NSCLC treated with chemoradiotherapy: a brief report. JTO Clin Res Rep. 2022;3: 100316. https://doi.org/10.1016/j.jtocrr.2022.100316.

Article  PubMed  PubMed Central  Google Scholar 

Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non–small-cell lung cancer: the phase III POSEIDON study. J Clin Oncol. 2023;41:1213–27. https://doi.org/10.1200/JCO.22.00975.

Article  CAS  PubMed